NewsBenzingaWells Fargo inicia cobertura de Denali Therapeutics con calificación de sobreponderar y anuncia un precio objetivo de 35 dólares Wells Fargo inicia cobertura de Denali Therapeutics con calificación de sobreponderar y anuncia un precio objetivo de 35 dólares Benzinga 2026.11.13 13:06 (GMT+0) Open on Benzinga Other news Nvidia’s $105 Billion OpenAI Bet Has a 20-Year Catch Freedom Broker Upgrades Espey Manufacturing to Buy, Maintains Price Target to $70 QUICK SPARK: Chip Stocks Eye Worst Two-Month Drop Since 2008 Carlyle, Clearlake Bet Big On Sports — And PE Deals Are Surging Target's $301 Million Tariff Windfall 'Flattered' Earnings, Analyst Says Freedom Broker Maintains Buy on SKYX Platforms, Lowers Price Target to $2